Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
1. Pfizer filed a lawsuit against Novo Nordisk and Metsera over anticompetitive claims. 2. Novo Nordisk's bid for Metsera values it around $6 billion, higher than Pfizer's. 3. Pfizer believes acquiring Metsera could enhance its foothold in the obesity market. 4. Metsera's obesity pipeline may introduce new competition in the weight loss drug sector. 5. Ongoing legal battles indicate uncertainty for Metsera's future and its acquisition.